When was Vaxxas founded?

Vaxxas was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is Vaxxas located?

Vaxxas is headquartered in Brisbane, Australia.

How many employees does Vaxxas have?

As of Jul 31, 2026, the latest employee count at Vaxxas is 130.

Is Vaxxas a funded company?

Vaxxas is a funded company, having raised a total of $91.2M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 02, 2011.

When was the latest funding round of Vaxxas?

Vaxxas' latest funding was a $***** Conventional Debt round on Aug 25, 2025, with participation from 1 investor.

Where does Vaxxas rank among its competitors?

Vaxxas ranks 3rd amongst 102 active competitors, of which 39 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Optimeos, which secured an undisclosed amount in Jun, 2026.

Who are the top competitors of Vaxxas?

Vaxxas' top competitors include scPharmaceuticals, CeQur and Hero Patch. Among them, Optimeos secured the most recent funding round in June, 2026.

Vaxxas - 2026 Company Profile, Team, Funding & Competitors

Vaxxas is a series D company based in Brisbane (Australia), founded in 2010. It operates as a Developer of a needle-free patch technology for vaccine delivery applications. Vaxxas has raised $91.2M in funding from investors like One Ventures, UniQuest and SPRIM Global Investments. The company has 102 active competitors, including 39 funded and 15 that have exited. Its top competitors include companies like scPharmaceuticals, CeQur and Hero Patch.

Company Details

Developer of a needle-free patch technology for vaccine delivery applications. The company’s technology uses a patch with microprojections applied to the skin. This approach aims to enhance vaccine efficiency and effectiveness. The company’s dry-coating technology reduces the need for vaccine refrigeration during storage and transport. The company targets applications in infectious disease and oncology.

Key Metrics

Founded Year

2010

Location

Brisbane, Australia

Stage

Series D

Total Funding

$91.2M in 9 rounds

Latest Funding Round

Conventional Debt, Aug 25, 2025, $*****

Investors

One Ventures & 13 more

Ranked

3^rd among 102 active competitors

Employee Count

130 as on Jul 31, 2026

Similar Companies

scPharmaceuticals & 131 more

View Vaxxas' full profile

Vaxxas has raised a total funding of $91.2M over 9 rounds. Its first funding round was on Aug 02, 2011. Its latest funding round was a Conventional Debt round on Aug 25, 2025 for $*****. 1 investor participated in its latest round. Vaxxas has 14 institutional investors.

Here is the list of recent funding rounds of Vaxxas:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2025	6459639	Conventional Debt	1321156	4097545	3158351	9994467
Aug 25, 2025	3908438	Series D	2098272	2897495	6941289	One Ventures & 1 more
Dec 05, 2022	2909175	Series C	1321910	5734486	One Ventures & 1 more	3177613

Access funding benchmarks and valuations. Sign up today!

View details of Vaxxas's funding rounds and investors

Vaxxas' employee count trend

Vaxxas has 130 employees as of Jul 26. Here is Vaxxas's employee count trend over the years:

Uncover Vaxxas' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vaxxas include scPharmaceuticals, CeQur and Hero Patch. Here is the list of Top 10 competitors of Vaxxas, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	scPharmaceuticals 2013, Lexington (United States), Acquired	Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure	$78.7M	Orbimed, Sun Pharma & 4 others	59/100
2nd	CeQur 2008, Horw (Switzerland), Series E	Developer of wearable insulin delivery patch	$492M	Endeavour Vision, Schroders & 7 others	59/100
3rd	Vaxxas 2010, Brisbane (Australia), Series D	Developer of a needle-free patch technology for vaccine delivery applications	$91.2M	Gates, Government of Australia & 12 others	59/100
4th	Hero Patch 2019, Boston (United States), Series A	Developer of antibodies or small molecules for drug delivery	$20.5M	Big Pi Ventures, Velocity Partners & 5 others	55/100
5th	Vaxinano 2016, Lille (France), Series A	Prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets	$6.48M	Nord France Amorquage, TCD Capital & 4 others	55/100
6th	Starton 2017, New York City (United States), Seed	Developer of drug delivery solution and drugs for treating oncology	$9.29M	LOVE Pharma, Goldfingr	52/100
7th	Scilex Holding 2019, Palo Alto (United States), Public	Developer of non-opioid therapies for acute and chronic pain	-	Frazier Life Sciences	52/100
8th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	52/100
9th	Optimeos 2016, Princeton (United States), Series A	Developer of drug delivery solutions by using biologics, peptides and RNA to treat multiple diseases	$4.19M	America’s Seed Fund, National Science Foundation ... & 2 others	50/100
10th	AFYX Therapeutics 2013, Copenhagen (Denmark), Series A	Developer of drug patches for the treatment of mucosal diseases	$33.3M	Sofinnova Investments, Nordic Venture & 6 others	47/100